277 related articles for article (PubMed ID: 32867461)
1. [Efficacy analysis of the radiotherapy and chemotherapy in patients with stage Ⅳ esophageal squamous carcinoma: a multicenter retrospective study of Jing-Jin-Ji Esophageal and Esophagogastric Cancer Radiotherapy Oncology Group (3JECROG R-01F)].
Hu MM; Yuan QQ; Zhang XS; Yang S; Wang X; Wang L; Chen JQ; Zhang WC; Wang XM; Ge XL; Shen WB; Xu YG; Hao CL; Zhou ZG; Qie S; Lu N; Pang QS; Zhao YD; Sun XC; Li GF; Li L; Qiao XY; Liu ML; Wang YD; Li C; Zhu SC; Han C; Zhang KX; Xiao ZF
Zhonghua Zhong Liu Za Zhi; 2020 Aug; 42(8):676-681. PubMed ID: 32867461
[No Abstract] [Full Text] [Related]
2. [Prognostic analysis of definitive radiotherapy for early esophageal carcinoma(T1-2N0M0): a multi-center retrospective study of Jing-Jin-ji Esophageal and Esophagogastric Cancer Radiotherapy Oncology Group].
Lu N; Wang X; Li C; Wang L; Chen JQ; Zhang WC; Wang XM; Ge XL; Shen WB; Hu MM; Yuan QQ; Xu YG; Hao CL; Zhou ZG; Qie S; Xiao ZF; Zhu SC; Han C; Qiao XY; Pang QS; Wang P; Zhao YD; Sun XC; Zhang KX; Li L; Li GF; Liu ML; Wang YD
Zhonghua Zhong Liu Za Zhi; 2020 Feb; 42(2):139-144. PubMed ID: 32135649
[No Abstract] [Full Text] [Related]
3. [Long-term efficacy and safety of simultaneous integrated boost radiotherapy in non-operative esophageal squamous cell carcinoma: a multicenter retrospective data analysis (3JECROG R-05)].
Wang XM; Wang L; Wang X; Chen JQ; Li C; Zhang WC; Ge XL; Shen WB; Hu MM; Yuan QQ; Xu YG; Hao CL; Zhou ZG; Qie S; Lu N; Han C; Pang QS; Wang P; Sun XC; Zhang KX; Li GF; Li L; Liu ML; Wang YD; Qiao XY; Zhu SC; Zhou ZM; Zhao YD; Xiao ZF
Zhonghua Zhong Liu Za Zhi; 2021 Aug; 43(8):889-896. PubMed ID: 34407597
[No Abstract] [Full Text] [Related]
4. A multicenter prospective phase III clinical randomized study of simultaneous integrated boost intensity-modulated radiotherapy with or without concurrent chemotherapy in patients with esophageal cancer: 3JECROG P-02 study protocol.
Gao LR; Wang X; Han W; Deng W; Li C; Wang X; Zhao Y; Ni W; Chang X; Zhou Z; Deng L; Wang W; Liu W; Liang J; Zhang T; Bi N; Wang J; Zhai Y; Feng Q; Lv J; Li L; Xiao Z
BMC Cancer; 2020 Sep; 20(1):901. PubMed ID: 32962674
[TBL] [Abstract][Full Text] [Related]
5. Clinical practice and outcome of radiotherapy for advanced esophageal squamous cell carcinoma between 2002 and 2018 in China: the multi-center 3JECROG Survey.
Li C; Wang X; Wang L; Chen J; Zhang W; Pang Q; Zhao Y; Sun X; Zhang K; Li G; Li L; Qiao X; Liu M; Wang Y; Deng L; Wang W; Bi N; Zhang T; Deng W; Ni W; Chang X; Han W; Zhou Z; Liang J; Feng Q; Wang L; Chen D; Lv J; Zhu S; Han C; Xiao Z
Acta Oncol; 2021 May; 60(5):627-634. PubMed ID: 33793382
[TBL] [Abstract][Full Text] [Related]
6. Comparison of involved field radiotherapy and elective nodal irradiation in combination with concurrent chemotherapy for T1bN0M0 esophageal cancer.
Nakatani Y; Kato K; Shoji H; Iwasa S; Honma Y; Takashima A; Ushijima T; Ito Y; Itami J; Boku N
Int J Clin Oncol; 2020 Jun; 25(6):1098-1104. PubMed ID: 32189155
[TBL] [Abstract][Full Text] [Related]
7. Salvage treatment for lymph node recurrence after radical resection of esophageal squamous cell carcinoma.
Chen J; Yin W; Yao H; Gu W
Radiat Oncol; 2019 Sep; 14(1):169. PubMed ID: 31533757
[TBL] [Abstract][Full Text] [Related]
8. A re-irradiation dose of 55-60 Gy improves the survival rate of patients with local recurrent esophageal squamous cell carcinoma after radiotherapy.
Wu X; Hu X; Chen J; He L
Radiat Oncol; 2021 Jun; 16(1):100. PubMed ID: 34103059
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the clinical efficacy between single-agent and dual-agent concurrent chemoradiotherapy in the treatment of unresectable esophageal squamous cell carcinoma: a multicenter retrospective analysis.
Li J; Gong Y; Diao P; Huang Q; Wen Y; Lin B; Cai H; Tian H; He B; Ji L; Guo P; Miao J; Du X
Radiat Oncol; 2018 Jan; 13(1):12. PubMed ID: 29357883
[TBL] [Abstract][Full Text] [Related]
10. Effects of intensity-modulated radiotherapy combined with chemotherapy and prognostic factors in patients with locally advanced oesophageal cancer.
Ou Y; Li H; Yang D; Suo L
Adv Med Sci; 2024 Mar; 69(1):125-131. PubMed ID: 38438081
[TBL] [Abstract][Full Text] [Related]
11. [The value of the planned neoadjuvant radiotherapy or chemoradiotherapy for the non-radical resection of esophageal squamous cell carcinoma].
Ni WJ; Deng W; Xiao ZF; Zhou ZM; Wang X; Chen DF; Feng QF; Liang J; Lyu JM; Bi N; Deng L; Zhang T; Wang WQ; Xue Q; Gao SG; Mu JW; Mao YS; Wang DL; Zhao J; Gao YS; Huang JF; Tan FW; Zhao L; Lyu F; Zhang GC
Zhonghua Zhong Liu Za Zhi; 2019 Apr; 41(4):295-302. PubMed ID: 31014056
[No Abstract] [Full Text] [Related]
12. Phase I Trial of Intensity-Modulated Hyperfractionated Radiotherapy Boost with Concurrent Chemotherapy Immediately Following Standard Chemoradiotherapy in Patients Primarily with Advanced Intra-thoracic/Cervical Esophageal Squamous Cell Carcinomas.
Cheng N; Liu Y; Zhao G; Xu Y; Zhang T; Chen Y; Yan G; Hu Y; Yao S; Wang Z; Wang C; Chen Z; Hu Z; Liu D; Chen T
Int J Radiat Oncol Biol Phys; 2020 Feb; 106(2):340-348. PubMed ID: 31655197
[TBL] [Abstract][Full Text] [Related]
13. Definite intensity-modulated radiotherapy with concurrent chemotherapy more than 4 cycles improved survival for patients with locally-advanced or inoperable esophageal squamous cell carcinoma.
Hsieh HY; Hsu CP; Yeh HL; Chuang CY; Lin JF; Chang CF
Kaohsiung J Med Sci; 2018 May; 34(5):281-289. PubMed ID: 29699635
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of simultaneous integrated boost intensity-modulated radiation therapy for esophageal squamous cell carcinoma in Chinese population: A single institution experience.
Xu Y; Wang Z; Liu G; Zheng X; Wang Y; Feng W; Lai X; Zhou X; Li P; Ma H; Wang J; Hu X; Chen M
J Cancer Res Ther; 2016 Oct; 12(Supplement):82-88. PubMed ID: 27721262
[TBL] [Abstract][Full Text] [Related]
15. [The efficacy and safety of high dose versus standard dose radiotherapy in concurrent chemoradiotherapy for patients with esophageal squamous cell carcinoma].
Ren XJ; Wang L; Han C; Liu LL
Zhonghua Zhong Liu Za Zhi; 2019 Feb; 41(2):135-139. PubMed ID: 30862144
[No Abstract] [Full Text] [Related]
16. Correlation of plasma miR-21 and miR-93 with radiotherapy and chemotherapy efficacy and prognosis in patients with esophageal squamous cell carcinoma.
Wang WT; Guo CQ; Cui GH; Zhao S
World J Gastroenterol; 2019 Oct; 25(37):5604-5618. PubMed ID: 31602161
[TBL] [Abstract][Full Text] [Related]
17. Chemoradiotherapy and Increased Prescription Dose in Esophageal Squamous Cell Cancer: A Retrospective Study.
Pan X; Liao M; Ma H; Jiang X; Huang H; Wei M; Li Q
Biomed Res Int; 2021; 2021():3834040. PubMed ID: 33628778
[TBL] [Abstract][Full Text] [Related]
18. Relative tumor volume is a better independent prognostic factor in esophageal squamous cell carcinoma: Results of a retrospective study.
Lv J; Gan H; Zhang W; Pan L; Wang R; Qin Y
Medicine (Baltimore); 2019 Apr; 98(14):e14963. PubMed ID: 30946321
[TBL] [Abstract][Full Text] [Related]
19. Involved-Field Irradiation in Definitive Chemoradiotherapy for Locoregional Esophageal Squamous Cell Carcinoma: Results From the ESO-Shanghai 1 Trial.
Zhu H; Rivin Del Campo E; Ye J; Simone CB; Zhu Z; Zhao W; Amini A; Zhou J; Wu C; Tang H; Fan M; Li L; Lin Q; Xia Y; Li Y; Li J; Mo M; Jia H; Lu S; Wang J; Nie Y; Chen J; Wu S; Hamaji M; Haque W; Jeong BK; Shridhar R; Zhang Z; Chen Y; Zhao K
Int J Radiat Oncol Biol Phys; 2021 Aug; 110(5):1396-1406. PubMed ID: 33677048
[TBL] [Abstract][Full Text] [Related]
20. Peripheral blood cell count ratios are predictive biomarkers of clinical response and prognosis for non-surgical esophageal squamous cell carcinoma patients treated with radiotherapy.
Zhi X; Jiang K; Shen Y; Su X; Wang K; Ma Y; Zhou L
J Clin Lab Anal; 2020 Oct; 34(10):e23468. PubMed ID: 32681567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
